{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 3,
  "pageCount": 415,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "testimonial",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses anonymous expert testimony to undermine the company's clinical trial integrity and market prospects.",
  "elementsJson": [
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/3",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-3",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "There was certainly some pressure on all the investigators to downplay the adverse effects",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64cd-733b-acab-25b4d1c385a4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.7,
        "x": 0.15,
        "y": 0.55
      },
      "kind": "quote",
      "text": "There was certainly some pressure on all the investigators to downplay the adverse effects...I was extremely uncomfortable with the direction from [redacted] to try and downplay things...",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1145771d-379c-4aa7-ac9c-161e4ae630e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.7,
        "x": 0.15,
        "y": 0.18
      },
      "kind": "quote",
      "text": "Very candidly, I'm kind of surprised that the FDA gave them an approval...other physicians are not so bullish about it...if you talk to some of the other investigators other than Jennifer Miller, you might get a different impression...",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2290063-f292-42f9-88f4-756c5df871b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"Very candidly, I'm kind of surprised that the FDA gave them an approval...other physicians are not so bullish about it...if you talk to some of the other investigators other than Jennifer Miller, you might get a different impression...I would say that you have a substantial number of investigators who are not so bullish about the drug\"; \"I fail to see how any third-party payor would accept this as a treatment...it's a little bit like the Sarepta drug...you have one devastating DKA and heart failure...they had some serious adverse effects where somebody was admitted to the ICU...I find it difficult to think that they will be able to really penetrate even a limited market...\"; \"There was certainly some pressure on all the investigators to downplay the adverse effects\"; \"I was extremely uncomfortable with the direction from [redacted] to try and downplay things...it's not what I would do...it's not what most normal companies would do...they wanted a successful outcome...all the people with significant incentive were the ones driving this train...\" — A former Soleno employee, one of several we interviewed involved with its clinical trials, along with a significant proportion of the company's trial investigators",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64cd-733b-acab-2bd2117e5c4a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.25,
        "y": 0.75
      },
      "kind": "source-note",
      "text": "-A former Soleno employee, one of several we interviewed involved with its clinical trials, along with a significant proportion of the company's trial investigators",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "108fc498-6f85-4a9c-8ea8-c3e7043cca9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0d9f134-b318-481a-a153-593563b68c1e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "48c0f4ed-baf6-4bc0-bb02-240eaf3d02c9",
      "evidence": "The slide uses expert testimony to allege manipulation of clinical trial results and pressure to downplay adverse effects.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}